Our Mission
Pioneering a New Era of GPCR Drug Discovery.
The Opportunity
Unlocking the full potential of G protein-coupled receptor (GPCR) drug targets creates the opportunity to develop the next generation of impactful new medicines for patients across therapeutic areas
What we do
Powered by our proprietary, industrial-scale Native Complex Platform™, we are discovering new ways to drug GPCRs
Our industrial-scale platform aims to unlock previously difficult-to-drug GPCRs and has led to the discovery, optimization, and development of our pipeline of oral small molecule drug candidates.
GPCRs regulate physiological processes in nearly every organ system of the human body
Pipeline
Septerna is a clinical-stage biotechnology company with a deep pipeline of oral small molecule GPCR drug candidates and discovery programs
We are advancing a wholly-owned pipeline focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
About Us
World-class team of drug hunters, GPCR experts, drug developers, and company builders
We are a strong, values-driven organization aimed at advancing cutting-edge science and relentlessly focused on developing a portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches for patients with significant unmet needs.
Collaboration powers our community
Press Releases
Latest News
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Septerna, Inc. (Nasdaq: SEPN), today reported financial results for the third quarter...
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering...
Septerna Prices Upsized Initial Public Offering
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering...
Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism
In addition to maintaining serum calcium control, PTH1R agonists upregulated bone turnover ...